Dual-purpose bone grafts improve healing and reduce infection.

Guelcher SA, Brown KV, Li B, Guda T, Lee BH, Wenke JC
J Orthop Trauma. 2011 25 (8): 477-82

PMID: 21738070 · DOI:10.1097/BOT.0b013e31821f624c

OBJECTIVE - To determine if a dual-purpose bone graft can regenerate bone and reduce infection in highly contaminated bone critical size defects in rats.

METHODS - Biodegradable polyurethane (PUR) scaffolds were loaded with recombinant human bone morphogenetic protein-2 (BMP-2) and vancomycin (Vanc). The release kinetics of the BMP-2 were tuned to take advantage of its mechanism of action (ie, an initial burst to recruit cells and sustained release to induce differentiation of the migrating cells). The Vanc release kinetics were designed to protect the graft from contamination until it is vascularized by having a burst for a week and remaining well over the minimum inhibitory concentration for Staphylococcus aureus for 2 months. The bone regeneration and infection reduction capability of these dual-purpose grafts (PUR+Vanc+BMP-2) were compared with collagen sponges loaded with BMP-2 (collagen+BMP-2) and PUR+BMP-2 in infected critical size rat femoral segmental defects.

RESULTS - The dual-delivery approach resulted in substantially more new bone formation and a modest improvement in infection than PUR+BMP-2 and collagen+BMP-2 treatments.

CONCLUSIONS - The PUR bone graft is injectable, provides a more sustained release of BMP-2 than the collagen sponge, and can release antibiotics for more than 8 weeks. Thus, the dual-delivery approach may improve patient outcomes of open fractures by protecting the osteoinductive graft from colonization until vascularization occurs. In addition, the more optimal release kinetics of BMP-2 may reduce nonunions and the amount of growth factor required.

MeSH Terms (14)

Animals Anti-Bacterial Agents Bone Morphogenetic Protein 2 Bone Transplantation Combined Modality Therapy Delayed-Action Preparations Femoral Fractures Fracture Healing Guided Tissue Regeneration Osteitis Rats Tissue Scaffolds Treatment Outcome Vancomycin

Connections (2)

This publication is referenced by other Labnodes entities: